Literature DB >> 25752281

Reproductive endocrinology: Menopausal hormone therapy-ovarian cancer risk revisited.

Susan R Davis1, Rodney Baber2.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 25752281     DOI: 10.1038/nrendo.2015.33

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

Review 1.  The domestic chicken: Causes and consequences of an egg a day.

Authors:  P A Johnson; C S Stephens; J R Giles
Journal:  Poult Sci       Date:  2015-02-09       Impact factor: 3.352

2.  Overdiagnosis and overtreatment in cancer: an opportunity for improvement.

Authors:  Laura J Esserman; Ian M Thompson; Brian Reid
Journal:  JAMA       Date:  2013-08-28       Impact factor: 56.272

3.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.

Authors:  Garnet L Anderson; Howard L Judd; Andrew M Kaunitz; David H Barad; Shirley A A Beresford; Mary Pettinger; James Liu; S Gene McNeeley; Ana Maria Lopez
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

4.  Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Joanne Kotsopoulos; Jan Lubinski; Jacek Gronwald; Cezary Cybulski; Rochelle Demsky; Susan L Neuhausen; Charmaine Kim-Sing; Nadine Tung; Susan Friedman; Leigha Senter; Jeffrey Weitzel; Beth Karlan; Pal Moller; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2014-12-18       Impact factor: 7.396

5.  Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.

Authors:  V Beral; R Doll; C Hermon; R Peto; G Reeves
Journal:  Lancet       Date:  2008-01-26       Impact factor: 79.321

6.  Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.

Authors:  Shelley S Tworoger; Kathleen M Fairfield; Graham A Colditz; Bernard A Rosner; Susan E Hankinson
Journal:  Am J Epidemiol       Date:  2007-07-26       Impact factor: 4.897

7.  Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

Authors:  JoAnn E Manson; Rowan T Chlebowski; Marcia L Stefanick; Aaron K Aragaki; Jacques E Rossouw; Ross L Prentice; Garnet Anderson; Barbara V Howard; Cynthia A Thomson; Andrea Z LaCroix; Jean Wactawski-Wende; Rebecca D Jackson; Marian Limacher; Karen L Margolis; Sylvia Wassertheil-Smoller; Shirley A Beresford; Jane A Cauley; Charles B Eaton; Margery Gass; Judith Hsia; Karen C Johnson; Charles Kooperberg; Lewis H Kuller; Cora E Lewis; Simin Liu; Lisa W Martin; Judith K Ockene; Mary Jo O'Sullivan; Lynda H Powell; Michael S Simon; Linda Van Horn; Mara Z Vitolins; Robert B Wallace
Journal:  JAMA       Date:  2013-10-02       Impact factor: 56.272

8.  Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years.

Authors:  Pragya Gartoulla; Roisin Worsley; Robin J Bell; Susan R Davis
Journal:  Menopause       Date:  2015-07       Impact factor: 3.310

9.  Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.

Authors:  V Beral; K Gaitskell; C Hermon; K Moser; G Reeves; R Peto
Journal:  Lancet       Date:  2015-02-13       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.